TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26141713

Group type: EXPERIMENTAL
Intervention: Fertility preservation counseling and information provided to patients and parents
Number of subjects: 290

Group type: COMPARATOR
Intervention: Pressure from doctors to reduce the delay between diagnosis and cancer treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Hope for future parenthood
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Medical support
Number of subjects: 290
Study: 26142620

Group type: EXPERIMENTAL
Intervention: Home use of mifepristone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Center use of mifepristone
Number of subjects: 400
Study: 26143178

Group type: EXPERIMENTAL
Intervention: Self-reported (SR) data via the internet
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-reported (SR) weight
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-reported (SR) BMI
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: BMI classification
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Anthropometric data (height, weight, BMI)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Genotype information
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Demographic data (age and sex verification)
Number of subjects: 140
Study: 26143264

Group type: EXPERIMENTAL
Intervention: Melanoma GVAX (5E7 cells/cycle, 2E8 cells/cycle, or 2E8 cells/cycle with cyclophosphamide 200 mg/m2) administered intradermally once every 28 days for four cycles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melanoma GVAX
Number of subjects: 20
Study: 26143343

Group type: EXPERIMENTAL
Intervention: Intravenous Sildenafil
Number of subjects: 2
Study: 26146564

Group type: EXPERIMENTAL
Intervention: Relative percent method (HRR group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Threshold based method (ACE-3ZM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 42
Study: 26147770

Group type: EXPERIMENTAL
Intervention: S-TOFHLA
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: NVS
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: S-TOFHLA (Spanish)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: NVS (Spanish)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: S-TOFHLA (English)
Number of subjects: 402
Study: 26148006

Group type: EXPERIMENTAL
Intervention: CLI patients not using aspirin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximal reactivity to stimulation of collagen and thrombin activation pathway in CLI patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CLI patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reactivity of platelets in CLI patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 26148170

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 0
Study: 26148518

Group type: EXPERIMENTAL
Intervention: Postoperative management with drains maintained for 7 days and bilirubin measured on postoperative days 3, 5, and 7.
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Pringle maneuvers lasting ≥90 min.
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Extended resections.
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Blood transfusions.
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Resections including segment I.
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Resections including segment V.
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis on POD 7.
Number of subjects: 475
Study: 26148750

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg orally 3 times/day) + Whole-Brain Radiotherapy (WBRT, 3.0 Gy per day, 5 days per week, to 30 Gy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Icotinib + WBRT
Number of subjects: 20
Study: 26148819

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S-ICD) system
Number of subjects: 55
Study: 26149529

Group type: EXPERIMENTAL
Intervention: VTV (viable tumor volume) criteria
Number of subjects: 17

Group type: COMPARATOR
Intervention: RECIST 1.1 response
Number of subjects: 17

Group type: COMPARATOR
Intervention: MASS criteria
Number of subjects: 17

Group type: COMPARATOR
Intervention: Choi criteria
Number of subjects: 17

Group type: COMPARATOR
Intervention: Volumetric measurements
Number of subjects: 17
Study: 26149600

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 20 mL injected bilaterally into the fascial plane between the multifidus and longissimus muscles
Number of subjects: 10
Study: 26150440

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 after two cycles
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 after two cycles with central review
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 at end of treatment with central review
Number of subjects: 138
Study: 26151791

Group type: EXPERIMENTAL
Intervention: Cryosurgery with 8-second freeze time
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cryosurgery with 12-second freeze time
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cryosurgery with freeze-times greater than 5 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cryosurgery with freeze-times greater than 8 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Histological analysis of blister roofs
Number of subjects: 8
Study: 26152123

Group type: EXPERIMENTAL
Intervention: Outdoor activity intervention (two additional 20-min recess programs outside the classroom)
Number of subjects: 3051

Group type: EXPERIMENTAL
Intervention: Outdoor activity intervention
Number of subjects: 3051
Study: 26152560

Group type: EXPERIMENTAL
Intervention: Catheter Contact Force (CF) ≥10 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increasing CF at a location where initial CF was <10 g and CF increased ≥4.5 g in sinus rhythm or ≥8 g in atrial fibrillation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Catheter orientation changed from perpendicular to parallel in atrial fibrillation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increasing CF at a location with initial CF <10 g and CF increased ≥8 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher CF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial CF ≥10 g
Number of subjects: 30
Study: 26153272

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein, soluble E-selectin, and soluble intercellular adhesion molecule-1 in type 2 diabetes
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IL-18 in type 1 diabetes
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: sE-selectin in type 2 diabetes
Number of subjects: 136
Study: 26153510

Group type: EXPERIMENTAL
Intervention: NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 200
Study: 26153531

Group type: EXPERIMENTAL
Intervention: LES-EST
Number of subjects: 44
Study: 26153726

Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin augmentation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched PiZZ individuals not on augmentation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: PiMZ participants not on augmentation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants from the Subpopulations and Intermediate Outcome Measures in COPD Study
Number of subjects: 0
Study: 26154653

Group type: EXPERIMENTAL
Intervention: Lap-Band AP implantation (post-LBAP)
Number of subjects: 585
Study: 26155776

Group type: EXPERIMENTAL
Intervention: Soluble EPCR variant (E86A-sEPCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CIDRα1.1 domain of PfEMP1
Number of subjects: 0
Study: 26155941

Group type: EXPERIMENTAL
Intervention: AMG 208 (oral MET inhibitor)
Number of subjects: 54
Study: 26155957

Group type: EXPERIMENTAL
Intervention: Low albuminuria (LA, 10-29 mg/24 h)
Number of subjects: 11538

Group type: COMPARATOR
Intervention: Normal albuminuria (NA, <10 mg/24 h)
Number of subjects: 11538

Group type: EXPERIMENTAL
Intervention: Use of anti-hyperglycaemic and anti-hypertensive agents
Number of subjects: 11538
Study: 26155994

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 93
Study: 26156015

Group type: EXPERIMENTAL
Intervention: 2D-TTE (A4C view)
Number of subjects: 282

Group type: COMPARATOR
Intervention: 3D-transesophageal echocardiography
Number of subjects: 282

Group type: COMPARATOR
Intervention: 2D-TTE (surgical measurements)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Healthy volunteers (A4C view)
Number of subjects: 282
Study: 26156652

Group type: EXPERIMENTAL
Intervention: High-dose chemoradiotherapy (60 Gy in 30 fractions to tumour, 50 Gy in 30 fractions to elective lymph node volumes, 5 Gy endorectal brachytherapy boost, and oral tegafur-uracil 300 mg/m(2) every weekday for 6 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Observation (watchful waiting) after chemoradiotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-dose chemoradiotherapy
Number of subjects: 55
Study: 26156741

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Serum metabolites
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adipose tissue gene expression
Number of subjects: 59
Study: 26156945

Group type: EXPERIMENTAL
Intervention: Geometric ring annuloplasty
Number of subjects: 65
Study: 26157075

Group type: EXPERIMENTAL
Intervention: BAX 855 (pegylated full-length recombinant FVIII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-demand treatment (licensed rFVIII - Advate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAX 855 (for treatment of bleeding episodes)
Number of subjects: 0
Study: 26158159

Group type: EXPERIMENTAL
Intervention: S-1 combination with oxaliplatin and oral leucovorin (SOL regimen)
Number of subjects: 21
Study: 26158171

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa/ribavirin
Number of subjects: 1604
Study: 26160357

Group type: EXPERIMENTAL
Intervention: Constant 24-h infusion (16.5 μg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant 7-day infusion (25.5 μg/day in Cohort 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-day escalation regimen (ranging from 7 to 58.5 μg/day in Cohort 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-day escalation regimen (25.5-58.5 μg/day in Cohort 3)
Number of subjects: 0
Study: 26160457

Group type: EXPERIMENTAL
Intervention: FTCQ-12 (French Tobacco Craving Questionnaire 12-item)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MNWS craving (Minnesota Nicotine Withdrawal Scale single craving item)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTCQ-12 RS (risk score from FTCQ-12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTCQ-12 RS and MNWS craving combined
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions targeting Expectancy and Purposefulness
Number of subjects: 0
Study: 26160744

Group type: EXPERIMENTAL
Intervention: Antiviral treatment (oseltamivir or zanamivir) in 474 patients.
Number of subjects: 914

Group type: COMPARATOR
Intervention: B/Victoria lineage
Number of subjects: 914

Group type: COMPARATOR
Intervention: B/Yamagata lineage
Number of subjects: 914
Study: 26160880

Group type: EXPERIMENTAL
Intervention: Panobinostat (10 mg) combined with idarubicin (8 mg/m(2) iv days 1-3) and cytarabine (100 mg/m(2) iv days 1-7) during induction, followed by panobinostat maintenance (40 mg po 3 days/week) every other week until progression.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Panobinostat monotherapy during maintenance phase for patients with persistent minimal residual disease.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Panobinostat maintenance phase.
Number of subjects: 38
Study: 26161281

Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy with double tract reconstruction (LPG with DTR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 0
Study: 26161450

Group type: EXPERIMENTAL
Intervention: TNFα soluble receptors 1 (TNFα-sR1)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: TNFα soluble receptors 2 (TNFα-sR2)
Number of subjects: 400

Group type: COMPARATOR
Intervention: PUFA intake
Number of subjects: 400
Study: 26161618

Group type: EXPERIMENTAL
Intervention: AXL1717, 390 mg BID for four weeks (RP2D)
Number of subjects: 55
Study: 26162031

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) treatment
Number of subjects: 108
Study: 26162676

Group type: EXPERIMENTAL
Intervention: Fluid challenges (FCs)
Number of subjects: 2213
Study: 26162857

Group type: EXPERIMENTAL
Intervention: J-CTO score
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Antegrade wiring techniques
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Retrograde approach
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Logistic regression model for technical success
Number of subjects: 650
Study: 26163041

Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy (initiation within 24 hours of hospital admission)
Number of subjects: 11944

Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy
Number of subjects: 11944

Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy in urban hospitals
Number of subjects: 11944

Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy in rural hospitals
Number of subjects: 11944
Study: 26163849

Group type: EXPERIMENTAL
Intervention: Modified Fujita Technique Uvulopalatoplasty (UPPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPAP treatment
Number of subjects: 0
Study: 26163959

Group type: EXPERIMENTAL
Intervention: Adhesiolysis during repeat median laparotomy
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Previous laparotomies
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: History of peritonitis, anatomical location of previous surgery, time interval between consecutive median laparotomies
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Presence or history of an intraperitoneal synthetic mesh
Number of subjects: 259
Study: 26164539

Group type: EXPERIMENTAL
Intervention: MMP-7 generated elastin fragments (ELM7) in patients with IPF
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: MMP-7 generated elastin fragments (ELM7) in patients with lung cancer
Number of subjects: 163
Study: 26167342

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group DL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope (Group TW)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (Group ATQ)
Number of subjects: 150
Study: 26167947

Group type: EXPERIMENTAL
Intervention: AvidinOX-pretargeted (90)Y-biotinDOTA
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 26168005

Group type: EXPERIMENTAL
Intervention: Influenza-attributable GP episodes for respiratory illness in children aged <5 years
Number of subjects: 857996

Group type: EXPERIMENTAL
Intervention: Influenza-attributable GP episodes for respiratory illness in seniors aged ≥75 years
Number of subjects: 857996

Group type: EXPERIMENTAL
Intervention: Antibiotic prescriptions resulting from influenza-attributable GP episodes
Number of subjects: 857996
Study: 26168322

Group type: EXPERIMENTAL
Intervention: Early multidetector chest CT scan
Number of subjects: 319
Study: 26169157

Group type: EXPERIMENTAL
Intervention: Total serum adiponectin concentrations measured by DuoSet® ELISA
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Reference intervals calculated using age as a continuous variable
Number of subjects: 1193
Study: 26169192

Group type: EXPERIMENTAL
Intervention: CONTOUR(®)PLUS
Number of subjects: 106
Study: 26169270

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection
Number of subjects: 0
Study: 26169613

Group type: EXPERIMENTAL
Intervention: Vismodegib (150 to 300 mg/d)
Number of subjects: 43
Study: 26169615

Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Week-1 [(18)F]FDG-PET/CT response
Number of subjects: 87
Study: 26169889

Group type: EXPERIMENTAL
Intervention: Single-sampling combined assessment of medium-sensitivity cardiac troponin I and ultra-sensitive copeptin
Number of subjects: 196

Group type: COMPARATOR
Intervention: Serial 0- and 3-hour medium-sensitivity cardiac troponin I sampling
Number of subjects: 196
Study: 26170105

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 162
Study: 26170136

Group type: EXPERIMENTAL
Intervention: Ombitasvir (25 mg), Paritaprevir (150 mg), and Ritonavir (100 mg) once daily for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, and Ritonavir regimen
Number of subjects: 181
Study: 26170350

Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy pregnancy
Number of subjects: 50
Study: 26170650

Group type: EXPERIMENTAL
Intervention: COPD presence in heart failure patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: COPD presence in heart failure with reduced ejection fraction
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: COPD presence in heart failure with preserved ejection fraction
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Newly detected cases of COPD in heart failure patients
Number of subjects: 106
Study: 26170884

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 15
Study: 26171276

Group type: EXPERIMENTAL
Intervention: V1512 (melevodopa 100 mg/carbidopa 25 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: L-dopa 100 mg/carbidopa 25 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: V1512 or L-dopa/carbidopa in combination with entacapone 200 mg
Number of subjects: 25
Study: 26171659

Group type: EXPERIMENTAL
Intervention: FreeStyle(®) Libre™ Flash glucose monitoring system
Number of subjects: 72
Study: 26171795

Group type: EXPERIMENTAL
Intervention: PLIN3 knockdown in myotubes from leans
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lipolytic stimulation (palmitate, forskolin, inomycin [PFI] cocktail)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Treatment with brefeldin A (BFA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PLIN3 protein content
Number of subjects: 29
Study: 26172064

Group type: EXPERIMENTAL
Intervention: Delayed story recall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrumental activities of daily living
Number of subjects: 0
Study: 26172205

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal mitomycin C (PL-MLP) at doses of 0.5-3.5 mg/kg every 4 weeks for up to 12 cycles
Number of subjects: 27
Study: 26173796

Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment
Number of subjects: 63
Study: 26174168

Group type: EXPERIMENTAL
Intervention: Top quartile of baseline BMI Z-scores (ages 8-10 years)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Age-specific BMI Z-scores at all youth clinic visits
Number of subjects: 182
Study: 26174313

Group type: EXPERIMENTAL
Intervention: Included patients (IN)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Excluded patients (OUT)
Number of subjects: 178
Study: 26174798

Group type: EXPERIMENTAL
Intervention: Left ventricular global function index (LVGFI)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 795
Study: 26175478

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3010
Study: 26175501

Group type: EXPERIMENTAL
Intervention: miR-339-5p (upregulated)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: miR-483-3p (upregulated)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: miR-139-5p (downregulated)
Number of subjects: 9
Study: 26175532

Group type: EXPERIMENTAL
Intervention: Oncology providers' documentation of falls
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Gait assessment by oncology providers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Referral to geriatrics or physical/occupational therapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Measurement of 25-hydroxy vitamin D level
Number of subjects: 125
Study: 26176325

Group type: EXPERIMENTAL
Intervention: K+D group (90 μg of vitamin K2 and 10 μg of cholecalciferol)
Number of subjects: 42

Group type: COMPARATOR
Intervention: D group (10 μg of cholecalciferol)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: K+D group
Number of subjects: 42

Group type: COMPARATOR
Intervention: D group
Number of subjects: 42
Study: 26176329

Group type: EXPERIMENTAL
Intervention: Anti-SAP antibody infusion after CPHPC treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPHPC treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anti-SAP antibody infusion
Number of subjects: 15
Study: 26176493

Group type: EXPERIMENTAL
Intervention: Low vitamin D levels (<30 ng/ml)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Normal vitamin D levels (≥30 ng/ml)
Number of subjects: 173
Study: 26176696

Group type: EXPERIMENTAL
Intervention: Lead-in therapy with intravenous silibinin 20 mg/kg/day for 14 days followed by triple-therapy (peginterferon-ribavirin and telaprevir) for 12 weeks, and peginterferon-ribavirin alone for 36 weeks.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lead-in therapy with intravenous silibinin
Number of subjects: 16
Study: 26177212

Group type: EXPERIMENTAL
Intervention: Heat-killed Campylobacter concisus, Campylobacter rectus, Selenomonas infelix, Porphyromonas endodontalis, Porphyromonas gingivalis, Tannerella forsythia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Campylobacter concisus, C. rectus, S. infelix
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eubacterium saphenum, Eubacterium nodatum, Filifactor alocis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porphyromonas endodontalis, Parvimonas micra
Number of subjects: 0
Study: 26177495

Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 330

Group type: COMPARATOR
Intervention: Women without PCOS (control group)
Number of subjects: 330